Telo Financial Statements From 2010 to 2024

TELO Stock  CAD 0.12  0.01  9.09%   
Telo Genomics financial statements provide useful quarterly and yearly information to potential Telo Genomics Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Telo Genomics financial statements helps investors assess Telo Genomics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Telo Genomics' valuation are summarized below:
Market Capitalization
8.6 M
Earnings Share
(0.04)
There are over one hundred nineteen available fundamental trend indicators for Telo Genomics Corp, which can be analyzed over time and compared to other ratios. All traders should should double-check Telo Genomics' current fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 4 M in 2024. Enterprise Value is likely to drop to about 4 M in 2024
Check Telo Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telo Genomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.5 K, Selling General Administrative of 1.6 M or Other Operating Expenses of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0. Telo financial statements analysis is a perfect complement when working with Telo Genomics Valuation or Volatility modules.
  
This module can also supplement various Telo Genomics Technical models . Check out the analysis of Telo Genomics Correlation against competitors.

Telo Genomics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.5 M3.4 M1.6 M
Slightly volatile
Total Current Liabilities362.7 K322.4 K310.6 K
Slightly volatile
Cash3.2 M3.1 M1.3 M
Slightly volatile
Non Current Assets Total70.6 K74.4 K370.3 K
Slightly volatile
Cash And Short Term Investments3.2 M3.1 M1.3 M
Slightly volatile
Liabilities And Stockholders Equity3.5 M3.4 M1.6 M
Slightly volatile
Other Stockholder Equity4.6 M6.9 M4.1 M
Slightly volatile
Total Liabilities378.2 K359.8 K325.4 K
Slightly volatile
Total Current Assets3.4 M3.3 M1.5 M
Slightly volatile
Net Receivables67.7 K57.4 K71.2 K
Pretty Stable
Common Stock Shares Outstanding72.6 M69.2 M32.2 M
Slightly volatile
Accumulated Other Comprehensive Income64.2 K37.8 K58.5 K
Slightly volatile
Accounts Payable162.5 K171 K310.8 K
Very volatile
Long Term Debt37.4 K29.2 K52.4 K
Slightly volatile
Intangible Assets520.3 K747.5 K529.9 K
Slightly volatile
Common Stock13.3 M24.9 M9.9 M
Slightly volatile
Property Plant Equipment19.6 K20.6 K88 K
Very volatile
Other Current Liabilities258.6 K252.3 K219.6 K
Slightly volatile
Other Liabilities13.6 K15.3 K16.7 K
Slightly volatile
Property Plant And Equipment Net56.7 K59.6 K273.5 K
Slightly volatile
Non Currrent Assets Other237.1 K161.7 K312.6 K
Slightly volatile
Other Assets357.5 K402.2 K438 K
Slightly volatile
Short and Long Term Debt Total27.8 K29.2 K182 K
Slightly volatile
Capital Stock18.7 M24.9 M14.8 M
Slightly volatile
Property Plant And Equipment Gross890.5 K1.1 M687.8 K
Slightly volatile

Telo Genomics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization54.5 K29.8 K67.8 K
Pretty Stable
Selling General Administrative1.6 M1.7 M1.3 M
Pretty Stable
Other Operating Expenses2.3 M3.2 M1.9 M
Slightly volatile
Total Operating Expenses2.3 M3.2 M1.9 M
Slightly volatile
Research Development834.8 K1.6 M618.8 K
Slightly volatile
Cost Of Revenue55.4 K38.1 K43.6 K
Slightly volatile
Reconciled Depreciation28.3 K29.8 K83.7 K
Slightly volatile

Telo Genomics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation228.5 K144.2 K447.3 K
Pretty Stable
Begin Period Cash Flow3.3 M3.1 M1.1 M
Slightly volatile
Total Cash From Financing Activities2.4 M3.1 M1.9 M
Slightly volatile
End Period Cash Flow3.2 M3.1 M1.4 M
Slightly volatile
Depreciation53.5 K29.8 K50.9 K
Slightly volatile
Other Cashflows From Investing Activities1.3 K1.3 K33.8 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables479.8 K507.8 K499 K
Slightly volatile
Capex To Depreciation5.540.12942.6882
Slightly volatile
Payables Turnover0.140.190.1623
Slightly volatile
Cash Per Share0.07230.01120.0532
Pretty Stable
Days Payables Outstanding2.5 KK2.4 K
Slightly volatile
Income Quality1.120.90640.8498
Pretty Stable
Intangibles To Total Assets0.01780.0170.0127
Pretty Stable
Current Ratio17.252.446913.8004
Pretty Stable
Graham Number0.210.08410.257
Slightly volatile
Capex Per Share0.09331.0E-40.0166
Pretty Stable
Average Receivables6.2 K6.5 K127.1 K
Slightly volatile
Interest Debt Per Share0.07841.0E-40.0229
Very volatile
Debt To Assets0.320.57430.6711
Slightly volatile
Days Of Payables Outstanding2.5 KK2.4 K
Slightly volatile
Ebt Per Ebit0.950.9980.995
Very volatile
Long Term Debt To Capitalization0.0240.01410.0378
Slightly volatile
Quick Ratio17.662.446913.8551
Pretty Stable
Cash Ratio9.142.119412.2771
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio6.221.00211.7254
Pretty Stable
Debt Ratio0.320.57430.6711
Slightly volatile

Telo Genomics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM13.2 M45.7 M
Slightly volatile
Enterprise ValueM12.4 M44.6 M
Slightly volatile

Telo Fundamental Market Drivers

Cash And Short Term Investments2.7 M

About Telo Genomics Financial Statements

Telo Genomics investors use historical fundamental indicators, such as Telo Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telo Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-924.8 K-971 K
Cost Of Revenue38.1 K55.4 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.